Eisai Past Earnings Performance
Past criteria checks 1/6
Eisai's earnings have been declining at an average annual rate of -23%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 2.7% per year. Eisai's return on equity is 5.1%, and it has net margins of 5.4%.
Key information
-23.0%
Earnings growth rate
-23.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 2.7% |
| Return on equity | 5.1% |
| Net Margin | 5.4% |
| Next Earnings Update | 07 Feb 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Eisai makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 753,221 | 40,970 | 382,177 | 168,009 |
| 30 Jun 24 | 733,845 | 32,648 | 387,882 | 169,347 |
| 31 Mar 24 | 741,751 | 42,406 | 364,084 | 169,021 |
| 31 Dec 23 | 749,460 | 45,421 | 346,208 | 176,070 |
| 30 Sep 23 | 759,329 | 48,096 | 346,619 | 174,257 |
| 30 Jun 23 | 757,075 | 48,874 | 341,916 | 175,647 |
| 31 Mar 23 | 744,402 | 55,432 | 348,139 | 172,999 |
| 31 Dec 22 | 737,098 | 26,705 | 373,875 | 169,848 |
| 30 Sep 22 | 752,500 | 32,233 | 382,752 | 173,324 |
| 30 Jun 22 | 741,594 | 32,690 | 374,428 | 168,422 |
| 31 Mar 22 | 756,226 | 47,954 | 356,847 | 171,738 |
| 31 Dec 21 | 712,935 | 57,311 | 317,150 | 165,418 |
| 30 Sep 21 | 691,250 | 62,508 | 293,153 | 162,699 |
| 30 Jun 21 | 679,253 | 59,855 | 282,369 | 161,584 |
| 31 Mar 21 | 645,942 | 42,119 | 272,568 | 150,299 |
| 31 Dec 20 | 707,888 | 93,682 | 271,476 | 145,248 |
| 30 Sep 20 | 713,400 | 120,571 | 261,973 | 139,628 |
| 30 Jun 20 | 707,203 | 124,523 | 253,516 | 141,217 |
| 31 Mar 20 | 695,621 | 121,767 | 248,554 | 140,116 |
| 31 Dec 19 | 661,646 | 96,659 | 244,091 | 146,367 |
| 30 Sep 19 | 631,974 | 57,725 | 239,503 | 147,863 |
| 30 Jun 19 | 643,531 | 72,747 | 233,180 | 140,143 |
| 31 Mar 19 | 642,834 | 63,386 | 223,798 | 144,844 |
| 31 Dec 18 | 627,367 | 63,714 | 212,469 | 139,100 |
| 30 Sep 18 | 625,106 | 65,679 | 195,229 | 138,461 |
| 30 Jun 18 | 611,499 | 54,347 | 186,198 | 140,514 |
| 31 Mar 18 | 600,054 | 51,845 | 179,915 | 139,579 |
| 31 Dec 17 | 569,814 | 29,048 | 178,312 | 134,955 |
| 30 Sep 17 | 554,276 | 30,269 | 178,090 | 123,639 |
| 30 Jun 17 | 544,027 | 29,425 | 176,249 | 119,503 |
| 31 Mar 17 | 539,097 | 39,358 | 175,633 | 112,478 |
| 31 Dec 16 | 530,696 | 55,031 | 175,240 | 110,471 |
| 30 Sep 16 | 542,313 | 71,812 | 178,825 | 114,420 |
| 30 Jun 16 | 545,602 | 69,227 | 182,036 | 115,750 |
| 31 Mar 16 | 547,922 | 54,933 | 188,227 | 122,307 |
| 31 Dec 15 | 566,435 | 44,886 | 192,375 | 125,396 |
| 30 Sep 15 | 554,912 | 43,871 | 191,627 | 132,652 |
| 30 Jun 15 | 554,885 | 43,021 | 192,617 | 135,534 |
| 31 Mar 15 | 548,465 | 43,254 | 189,910 | 131,907 |
| 31 Dec 14 | 560,795 | 40,152 | 90,324 | 228,412 |
| 30 Sep 14 | 561,938 | 15,717 | 126,410 | 192,643 |
| 30 Jun 14 | 578,945 | 29,225 | 163,903 | 159,644 |
| 31 Mar 14 | 600,363 | 32,955 | 210,544 | 130,544 |
| 31 Dec 13 | 590,152 | 43,756 | 223,092 | 120,377 |
Quality Earnings: ESAL.F has high quality earnings.
Growing Profit Margin: ESAL.F's current net profit margins (5.4%) are lower than last year (6.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ESAL.F's earnings have declined by 23% per year over the past 5 years.
Accelerating Growth: ESAL.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ESAL.F had negative earnings growth (-14.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (54.6%).
Return on Equity
High ROE: ESAL.F's Return on Equity (5.1%) is considered low.